Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Código da empresaFEMY
Nome da EmpresaFemasys Inc
Data de listagemJun 18, 2021
CEOLee-Sepsick (Kathy)
Número de funcionários69
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 18
Endereço3950 Johns Creek Court
CidadeSUWANEE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal30024
Telefone17705003910
Sitehttps://www.femasys.com/
Código da empresaFEMY
Data de listagemJun 18, 2021
CEOLee-Sepsick (Kathy)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados